- Compugen (NASDAQ:CGEN) announces that the FDA has signed off on Bayer AG's (OTCPK:BAYRY) IND for cancer candidate BAY 1905254, an immuno-oncology therapeutic antibody targeting the ILDR2 protein in solid tumors.
- ILDR2 is an immune checkpoint discovered by Compugen (CGEN). Phase 1 development should start later this year.
- CGEN is up 11% premarket.
- Previously: Compugen up 10% as FDA pulls clinical hold (July 2)
Bayer on go with clinical development of Compugen-discovered therapeutic antibody
Recommended For You
About CGEN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CGEN | - | - |
Compugen Ltd. |